AIDS Healthcare Foundation brings free HIV testing and PrEP access to Las Vegas with an electric mobile clinic. See what its expansion means for care.
Quanta System's ICE26 recognition brings its urology lasers, clinical evidence, US expansion and 2027 development plans into focus.
Genentech's vamikibart sustained vision gains at 52 weeks, but mixed Phase III results leave questions ahead of a July 2027 FDA decision.
Haag-Streit launches Octopus 910 in the US with automated glaucoma testing and HFA data import. Can it improve clinical workflows?
Natera’s multi-cancer blood test wins FDA Breakthrough Device status after a 12-cancer review, but full performance data remain undisclosed.
Perceptive Discovery and Nucleus RadioPharma link imaging and manufacturing to address critical bottlenecks in radiopharmaceutical development.
RingConn's FDA-cleared blood oxygen ring marks a medical wearable milestone, but device scope and clinical adoption remain critical.
FDA approves Hovilpri for refractory HSV after 63% lesion healing in Phase 3. See how pritelivir changes treatment and Asahi Kasei's outlook.
Abbott Laboratories (NYSE: ABT) has received United States Food and Drug Administration approval for new patient-facing capabilities within its CardioMEMS HF System, allowing care teams to give patients access to pulmonary artery pressure trends through the CardioGuide HF App. The update also introduces a Dynamic Treatment Plan feature through which clinicians can communicate personalised medication
GRAIL shares recorded their strongest session in more than a year after FDA reviewers raised no major analytical or primary safety concerns ahead of a September 23 advisory committee vote on Galleri, the blood test designed to screen adults for signals from more than 50 cancers.